The infection by the 2019-nCoV coronavirus (COVID-19) is a world-wide emergency. The crystal structure of a protein essential for virus replication has been filed in the Protein Data Bank recently. Additionally, homology models of 24 COVID-19 proteins were made available by the Zhang group. In this paper, we present results deriving from the virtual screening of a database of more than 3000 FDA approved drugs on two distinct targets. Results showed that some of the known protease inhibitors currently used in HIV infections might be helpful for the therapy of COVID-19 also.
4MDS: the crystal structure of SARS-CoV 3CL-PRO proteinase, that is a close homologue of COVID-19 3CL-PRO proteinase, in complex with a carboxamide inhibitor was also downloaded and used as a reference. [11] The system was prepared for calculations as follow: the PDB was corrected and protonated at pH=7.0 using MOE as stated above. The ligand was minimized, keeping the receptor constrained, using the MMFF94x forcefield coupled with the Born solvation model. The receptor was then minimized, keeping the ligand constrained, using Amber10EHT+Born. Finally, the complex was minimized in two steps, as described above. QHD43415: the I-TASSER model QHD43415_5 [6] was superposed to 4MDS (prepared as previously described) in order to define the precise binding site. Since we observed that the 4MDS ligand also fitted QHD43415_5, the ligand was transferred, and the complex was prepared as described for 4MDS. The resulting structure was used for docking.
Database preparation.
Two separate databases were downloaded from the corresponding sources [8, 9] and merged. The database was then checked for redundancy and redundant molecules, identified by CAS number, were removed. The database was then processed by MOE in order to build the 3D structure and to minimize the geometry of each molecule. The Wash function of the MOE database tool was used with the MMFF94x+Born force field, requesting the dominant protonation state at pH=7.0 and preserving existing chirality. The final database, consisting of 3118 unique molecules, was saved in SDF format.
Virtual Screening.
The Virtual Screening (VS) was done accordingly to our recently developed protocol. [12] The protocol is applied using a set of scripts (available for download as Supplementary Material within ref. [12] ) that do the following steps automatically: 1. Preparation of the screening library. 2. Docking of all molecules (and corresponding tautomers, protonation states and ring conformers, if requested) using PLANTS [13] . 3. Analysis of results 4. Parameterization of docked ligands selected for rescoring. 5. Molecular dynamics of complexes selected for rescoring, using Amber [14] . Rescoring using the Nwat-MMGBSA method. [12, 15] All screenings were performed by using the ligand database prepared as stated before (no tautomers or alternative protonation states). The following parameters were set for the screenings: 6LU7: center="-10.2858 12.3088 69.3271", rad=16, speed=1, sfunct=chemplp QHD43415: center="-15.124 15.0521 -24.6152", rad=14, speed=1, sfunct=chemplp Nwat-MMGBSA rescoring was requested for the top 1% compounds (about 30 molecules for each target). Rescoring consist in performing a short MD simulation (about 2.5 ns, including 1.5 ns of equilibration and 1 ns of production), followed by calculation of binding energy by MMGBSA [16] using the default protocol (Nwat=0) or selecting a certain number of explicit waters to be included in the calculation, accordingly to the Nwat-MMGBSA method (in this case, rescoring was repeated using Nwat=10, 20, 30, 60 and 100). The same protocol was also applied to 4MDS, since the binding energy computed for the 4MDS crystallographic ligand was used as a reference. Analogously, the binding energy of the 6LU7 ligand (whose covalent bond was broken as described above), was computed as a reference.
Results and discussion.
The results of the VS campaign conducted on COVID-19 main protease (PDB code 6LU7) and on COVID-19 3CL-PRO proteinase are summarized in Tables 1 and 2, respectively. Results of Nwat-MMGBSA rescoring, using 30 explicit waters, are the only reported, since Nwat=30 was considered a reasonable value in previous publications. [12, 15] As it can be observed, the protease inhibitor Indinavir, [16] currently used to treat HIV infections, has been selected by both targets. Additionally, the other protease inhibitors Lopinavir [17] and Atazanavir [18] are also top ranked for 3CL-PRO. Cobicistat, another drug that is approved for the treatment of HIV infection, has been selected as a potential COVID-19 main protease inhibitor, even if its main mechanism is claimed to be the inhibition of CYP3A. [19] Angiotensin II and GHRP-2 are also selected in both screenings. However, it should be considered that both Angiotensin II and GHRP-2 are peptides, and so they are likely to be substrates for proteases. Even if they might bind the target, they would be rapidly cleaved by the target itself. Thus, we consider both compounds as false positives. The identification of Capsofungin, an antifungal drug specifically used in HIV-infected individuals [20] is also unexpected. Considering the macrocyclic structure of Capsofungin, together with the large number of rotatable bonds, we expect the docking of such a molecule to be rather challenging and so we have some doubts upon the reliability of this results. Several other compounds were selected by docking but failed during the molecular dynamic simulation. Such a failure might be due to several causes, among all poor parameterization (the BCC charge parameterization method [21] is chosen for time constraints). However, the reason of the failure might also be due to severe steric clashes or mispositioning during the docking stage. Thus, although some good hit might be found within the "F" series, these selections are considered the least reliable. Further calculations with more reliable (but much more time-consuming) parameterization schemes should be made to confirm whether or not these compounds are potential COVID-19 main protease or 3CL-PRO proteinase inhibitors.
